Press Review

September 2011

Cytokine-Based Therapies and Inhibitors: R&D Pipelines, Markets, and Strategic Issues

Expert Interview:  Hubert Heinrichs, MD, PhD, Chief Medical Officer and Acting CEO, and Andrea Kottke, PhD, Head of Marketing, Antisense Pharma  mehr

Source: Insight Pharma Reports

April 2011

Oligonucleotide Production Gearing Up

Oligonucleotide-based drugs continue to flow into developmental pipelines, and the relatively large numbers now being tested in humans and progressing through late-stage clinical studies have buoyed optimism that... more

Source: GEN (Genetic Engineering & Biotechnology News, print & online)

February 2011

Antisense gets South Korean & Taiwanese nod for studies using anti-cancer drug trabedersen in brain tumour

The biopharmaceutical company Antisense Pharma announced that the South Korean health agency KFDA as well as the Taiwanese health agency TFDA has granted their approvals for the implementation of clinical studies using the... mehr

Source: Pharmabiz.com

February 2011

Antisense Pharma Receives Approval for Clinical Studies in South Korea and Taiwan in Malignant Brain Tumors

The biopharmaceutical company Antisense Pharma today announced that the South Korean health agency KFDA as well as the Taiwanese health agency TFDA have granted their approvals for the implementation of clinical studies using... mehr

Source: CheckOrphan.org

February 2011

Antisense receives approval to conduct cancer drug trials in Korea, Taiwan

Antisense Pharma has reported that the South Korean health agency KFDA and the Taiwanese health agency TFDA have granted their approvals to conduct clinical studies of the anti-cancer drug trabedersen for patients with... mehr

Source: PBR Clinical Trials

February 2011

Antisense Pharma Receives Approval for Clinical Studies in South Korea and Taiwan in Malignant Brain Tumors

Antisense Pharma Receives Approval for Clinical Studies in South Korea and Taiwan in Malignant Brain Tumors With this approval, the Southeast Asian health agencies KFDA and TFDA have paved the way for the implementation of the... mehr

Source: FierceBiotech.com

February 2011

Antisense Pharma Receives Approval for Clinical Studies in South Korea and Taiwan in Malignant ...

With this approval, the Southeast Asian health agencies KFDA and TFDA have paved the way for the implementation of the pivotal Phase III study SAPPHIRE with the TGF-β2 inhibitor trabedersen Regensburg, Germany, February 2, 2011... mehr

Source: BioPortfolio.com

February 2011

Antisense receive approval for trabedersen studies in South Korea/Taiwan

The Food and Drug Administrations in both Korea and Taiwan have granted approval for the implementation of clinical studies of Antisense Pharma's trabedersen mehr

Source: Cancer Drug News